Background: Protein kinase CK2 (also known as casein kinase 2) is a messenger-independent protein serine/
INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) comprises approximately 90% of the malignancies of the head and neck (1, 2) . These are aggressive neoplasms which pose a significant international public health problem (1-3); in the United States alone, more than 40,000 new cases are diagnosed annually. In spite of a steady increase in incidence, and the significant morbidity and mortality carried with it, advances in treatment have not resulted in measurable improvement in overall survival; one-third of these patients die within 5 years despite multimodality therapy (4, 5) . Although early diagnosis has been demonstrated to improve overall survival rates in these patients, proper recognition of the malignant potential of SCCHN lesions has 660 Molecular Medicine, Volume 1, Number 6, September 1995 been hindered by a lack of observer-independent histopathologic criteria and cellular markers of aggressive tumor behavior (6) (7) (8) . An improved understanding of the biological aggressiveness, or malignant potential, of a particular tumor at the time of presentation would allow for prudent choices among treatment options, and would ideally contribute to therapeutic advancements. While some biomarkers of malignant transformation in SCCHN have been advanced, none have yet proven to be clinically useful (7) (8) (9) (10) (11) (12) (13) .
Recent advances in the field of regulatory protein phosphorylation may provide a promising area for clinical research focussed on potential prognostic markers. Phosphorylation of proteins as a post-translational modification is considered to play a pivotal role in the regulation of cellular growth and differentiation (reviewed in Refs. [14] [15] [16] CK2 is a ubiquitous serine/threonine kinase known to occur as a tetrameric complex of a (Mr 41,000), a' (Mr 38,000), and 03 (Mr 28,000) subunits, with an a2/2 or aa'fB2 configuration, and is localized in both cytosolic and nuclear subcellular compartments (reviewed in Ref. 18 ). CK2 is a multipotential enzyme, and is reported to phosphorylate a number of substrates known to play a pivotal role in cell division and differentiation (18) . There is evidence that CK2 may transmit signals to the nucleus by its translocation between the cytoplasm and the nucleus in response to growth stimuli (19) (20) (21) . Furthermore, several reports suggest that CK2 activity is modulated by various agents, including steroid hormones, insulin, and epidermal growth factor (EGF) (18, 19, 22, 23) . CK2 activation has been associated with malignant transformation. As examples, elevated levels of CK2 activity have been detected in human prostatic, lung, and colon carcinomas (19, 24, 25) . The role of CK2 as an oncogene is further supported by a recent report that overexpression of CK2 in the lymphocytic compartment of transgenic mice is capable of transforming lymphocytes (26 Quantitation of CK2 Activity Protein kinase CK2 activity in nuclear extracts and cytosolic fractions was measured using the specific CK2 synthetic decapeptide substrate, [Arg-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu], as described (21 ship between CK2 activity in cytosol and nuclear fractions of SCCHN tumors and normal mucosa is apparent in Fig. 1 .
Association of CK2 Expression with Clinicopathologic Parameters
The observation that both cytosolic and nuclear levels of CK2 activity were significantly elevated in SCCHN tumors ( Fig. 1 ) prompted us to exam- Fig. 2A) . Second, higher cytosolic CK2 activity was associated (p < 0.056) with metastatic behavior: those tumors having histopathologically proven lymph node metastases exhibited higher cytosolic CK2 activity than those that were negative for metastases (Fig. 2B) Fig. 2C . In this study population, we had no patients who were alive with disease/recurrence. When patients were divided into two groups based on the median cytosolic CK2 activity (4.8), patients in the Low-CK2 activity group exhibited significantly greater cumulative survival than those patients in the High-CK2 activity group (p < 0.023). Cox survival analysis revealed a relative risk-ratio for SCCHN tumor-cytosolic CK2 activity of 1.43. The Kaplan-Meier analysis of these data is illustrated in Fig. 3 .
In contrast to the above associations, CK2 activity in the soluble nuclear fraction of SCCHN tumor samples revealed no (19, 24, 25) , but correlation of CK2 activity in subcellular compartments with clinicopathologic parameters has not been previously examined in detail. The present data provide the first account of the subcellular compartmentation of CK2 activity in human tumors, and the association of CK2 activity within subcellular compartments with tumor behavior. Interestingly, although the nuclear fractions of SCCHN tumors exhibited the highest CK2 activities, the data did not reveal a significant correlation between these nuclear activities and clinicopathological parameters. Confirmation of the subcellular localization of CK2 in SCCHN using immunohistochemical methods is currently under way, and further investigation into the subnuclear localization of CK2 in SCCHN seems warranted.
These initial data suggest that cytosolic CK2 activity in the primary SCCHN tumors may be related to metastatic tumor behavior. Inasmuch as the presence of cervical lymph node metastases reduces 5-year survival by nearly 45% (28) , this observation is clearly related to the correlation between CK2 activity and clinical outcome suggested by the present data. However, it is not possible to infer from the present data which aspects of the metastatic process may be linked to CK2 activity, especially since we did not quantitate CK2 activity in either tumor recurrences or nodal metastases. Similarly, we did not study CK2 activity levels in oropharyngeal mucosa with respect to staged tumor progression per se (hyperplasia through carcinoma), as has been described for expression of proliferating cell nuclear antigen (9) and EGF receptors (10) in the multistep process of SCCHN tumorigenesis; follow-up studies of CK2 in these tissues are indicated. Finally, it may promote our understanding of the pathogenesis of this malignancy to determine whether the elevated levels of CK2 activity detected in SCCHN reflect transcriptional, translational, or post-translational levels of activation.
In summary, the data presented here, although preliminary, suggest that the Protein Kinase CK2 is activated with malignant transformation of upper aerodigestive tract mucosa to SCCHN, and that CK2 may play a significant role in the pathobiology of SCCHN. Investigation into the molecular basis of these novel findings, as well as follow-up study of CK2 in additional tissues, seems warranted, as these questions bear directly on the relationship between this protein kinase and SCCHN tumorigenesis.
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